Join the study to help researchers, healthcare providers, and other patients learn about the safety of using CIBINQO (abrocitinib) and other medications used for the treatment of moderate-to-severe atopic dermatitis during pregnancy. A pregnancy registry is a study that collects health information from women who take prescription medicines when they are pregnant.
Call the registry team toll-free at 1-877-311-3770 (hours of operation 8.30am - 5.00pm EST Monday-Friday)
Download the study database or app by clicking here. When prompted for a registration code enter USA-8903-0474. This option is only available for adults. If you are a minor, please contact the registry directly.
CIBINQO is a prescription medicine to treat adults with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.
It is not known if CIBINQO is safe and effective in children.
It is for the:
Treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Future pregnant women with moderate-to-severe atopic dermatitis, their healthcare providers, and researchers can benefit from the information you provide to the registry.
If you are eligible and would like to participate, you will be asked to:
Provide your consent (a requirement for participation in any research study)
Give the registry permission to contact your healthcare provider(s) to collect information for the study
You and your healthcare provider(s) will provide information to the registry about your pregnancy and your baby’s health up to 1 year of age.
This information can be provided by completing paper forms, via the free registry app, via the website portal or via short phone interviews with one of the registry staff members. Only information normally documented in your medical record will be collected.
If you participate, there will be:
No extra doctor’s visits or additional testing
No changes to your existing healthcare provider(s) or care
You and your healthcare provider(s) will receive compensation for providing data to the registry.
If you are eligible and would like to participate, you will be asked to provide information to the registry at enrollment and periodically throughout your pregnancy:
At enrollment, you will be asked to provide basic information about yourself (e.g., race, ethnicity, education, height, and weight) and information about your history of moderate-to-severe atopic dermatitis.
You will be paid for the data you provide to the registry.